DrugVoice connects Talking Medicines’ Message Resonance Score™ with near-real-time point-of-care intent signals to reveal what resonates with clinicians, how it relates to intent-to-prescribe, and where patients could benefit. 

GLASGOW, Scotland – September 16, 2026 – Talking Medicines, the advanced data science and AI company for life sciences, today announced the launch of the new intent to prescribe application within DrugVoice, enabled through new partnerships with point-of-care data providers. 

By combining message resonance intelligence with point-of-care signals, the DrugVoice application helps Pharmaceutical companies identify which clinicians are aligned with their messaging and examine the association between that alignment and prescribing intent in near-real- time. 

Pharma invests billions each year in communications intended to inform healthcare professionals and influence decision-making. Yet brand, medical, and insights teams often lack an evidence-based way to understand which individual clinicians are most aligned with their messages or whether that alignment is associated with an increased intent to prescribe. 

Put simply, traditional measures such as reach and engagement do not answer the bigger question: Which messages resonate with the clinicians that matter, and is stronger resonance associated with greater intent-to-prescribe? 

Talking Medicines addresses this blind spot by bringing together two distinct intelligence layers: 

• Message Resonance Score™ identifies alignment between clinicians and specific messages using curated real-life data and advanced data science, revealing what resonates, with whom, and why. 

• Point-of-care data provides near-real-time signals of prescribing intent within the clinical workflow. 

Bringing these layers together enables teams to identify clinicians showing stronger alignment with priority messaging and examine how that alignment relates to prescribing intent at the point of care. 

The intelligence can help Pharma companies and their agency partners: 

• Identify the clinicians most aligned with priority messages 

• Understand what resonates across personas 

• Examine associations between message alignment and intent to prescribe 

• Reveal potential gaps between prescribing intent and subsequent behavior 

• Inform more relevant medical and commercial communications 

• Monitor changes around launches, campaigns, congresses, and other key moments 

“Pharma has no shortage of engagement data, but engagement alone does not show which clinicians are aligned with its messaging,” said Jo Halliday, CEO of Talking Medicines. “The question is whether a message resonates with the right clinician and whether that alignment is associated with intent to act. DrugVoice creates this intelligence layer.” 

Intent-to-prescribe is one of several applications of DrugVoice Message Resonance Score™. The proprietary framework can also be used to benchmark positioning and messaging, validate personas, compare resonance across Healthcare Professionals, Opinion Leaders, Patients, and Consumers, and monitor changes over time, helping Pharma companies move beyond communication activity to understand what resonates and what to do next. 

As Pharmaceutical leaders gather in Philadelphia to discuss the future of marketing, medical affairs, commercialization, data, and AI, the ability to connect communications intelligence more closely with decision-making and patient opportunity is becoming increasingly important. 

“Message performance should not stop at whether content was seen or clicked,” Halliday continued. “The more valuable question is whether the message aligns with the right clinician and whether that alignment is associated with intent to act. Understanding what resonates, with whom, and why gives Pharma a stronger intelligence layer for deciding what to do next.” 

DrugVoice transforms curated, unstructured real-life healthcare professional, patient, and consumer data into structured, governed intelligence using advanced data science and AI. Its natural-language interface allows teams to ask questions in their own words and receive clear, evidence-based answers grounded in the underlying data. 

Know what resonates. Understand intent. Unlock Patient uptake. 

The intent to prescribe application is available through tailored DrugVoice intelligence programs for Pharmaceutical companies and their Agency partners, with point-of-care intent signals enabled through Talking Medicines’ new data partnerships. 

To learn more or request a demonstration – Get in Touch 

ABOUT TALKING MEDICINES 

Talking Medicines is an advanced data science and AI company for life sciences. Its DrugVoice platform transforms real-life voice data from healthcare professionals, patients, and consumers into structured, governed intelligence that helps pharmaceutical companies and their agency partners understand audiences, quantify message resonance, and make more evidence-based commercial and medical decisions. 

Through its proprietary DrugVoice Message Resonance Score™, Talking Medicines identifies what resonates, with whom, and why, helping Pharma connect healthcare voice with intent and Patient opportunity. 

From noise to signals. From signals to intelligence. Real conversations. Measurable impact.